You are here: Industry Insights > ASO

News List

Making Sense of Antisense: The Power of Gene Silencing February 11, 2025
This article explores antisense oligonucleotides (ASOs) in gene silencing, covering their mechanism, development, applications, pros and cons, and future delivery challenges.
n-Lorem Foundation Partners with Argonaut Manufacturing Services contractpharma
February 03, 2022
Will make ASO medicines for patients with nano-rare diseases.
FDA Issues Draft Guidance on Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products americanpharmaceuticalreview
April 29, 2021
The U.S. Food and Drug Administration has issued the draft guidance “Nonclinical Testing of Individualized Antisense Oligonucleotide (ASO) Drug Products for Severely Debilitating or Life-Threatening Diseases - Guidance for Sponsor-Investigators.”
Aro Biotherapeutics signs licensing agreement worth up to $1.4bn pharmaceutical-technology
January 13, 2020
Aro Biotherapeutics, a biotech firm engaged in the development of protein biologics called Centyrins, has signed a licencing deal that can potentially generate up to $1.4bn for the company.